ABEA

Avantor Wins Five Prestigious Awards at Asia-Pacific Biopharma Excellence Awards 2024

Retrieved on: 
Thursday, March 21, 2024
Yee, Organization, Growth, ABEA, Management

SINGAPORE, Mar 21, 2024 - (ACN Newswire) - Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences advanced technologies industries, has secured five prestigious awards at the esteemed Asia-Pacific Biopharma Excellence Awards (ABEA)2024.

Key Points: 
  • SINGAPORE, Mar 21, 2024 - (ACN Newswire) - Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences advanced technologies industries, has secured five prestigious awards at the esteemed Asia-Pacific Biopharma Excellence Awards (ABEA)2024.
  • Avantor sweeps 5 Biopharma Award at the Asia Pacific Biopharma Excellence Awards 2024 in Singapore.
  • "These awards are a testament to the dedication and expertise of our Avantor team," remarked Christophe Couturier, Executive Vice President of AMEA, Avantor.
  • The Asia-Pacific Biopharma Excellence Awards (ABEA) recognizes exceptional Asian bioprocessing, biologistic, clinical trials and aseptic fill and finish experts, organizations and technologies.

INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

Retrieved on: 
Thursday, September 7, 2023
DNA, TRIO, Contract research organization, Civil service commission, Face, RRP, Food, ABEA, Cancer, Infection, Breakthrough therapy, Orphan drug, Patient, ALA, Annual general meeting, Breakthrough, HPV, Recurrence, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, European Commission, Pharmaceutical industry, Laryngoscopy

PLYMOUTH MEETING, Pa., Sept. 7, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for INO-3107 as a potential treatment for patients with Recurrent Respiratory Papillomatosis (RRP). The FDA's Breakthrough Therapy designation is a process designed to expedite the development and review of drug candidates that are intended to treat a serious or life-threatening condition and for which preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).

Key Points: 
  • "As we recently announced, we have been interacting with the FDA with the goal to launch a pivotal trial for INO-3107 in the near term.
  • The President of the Recurrent Respiratory Papillomatosis Foundation, Kim McClellan, said: "RRP patients will tell you that even one reduction in the number of disruptive, invasive surgeries they face would be life-changing.
  • This Breakthrough Therapy designation for INO-3107 follows receipt of Orphan Drug designation from the European Commission in May 2023 and from the FDA in 2020.
  • INOVIO plans to initiate a pivotal trial of INO-3107 in the first quarter of 2024, subject to FDA clearance.

INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023

Retrieved on: 
Thursday, April 27, 2023
DNA, RRP, ABEA, Cancer, Lead, Infection, Patient, Recurrence, Electroporation, Safety, Vaccine

PLYMOUTH MEETING, Pa., April 27, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that an abstract has been accepted for oral presentation on INO-3107 for the treatment of Recurrent Respiratory Papillomatosis (RRP) at this year's American Broncho-Esophagological Association (ABEA) program at the Combined Otolaryngology Spring Meetings (COSM) in Boston, Massachusetts.

Key Points: 
  • PLYMOUTH MEETING, Pa., April 27, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that an abstract has been accepted for oral presentation on INO-3107 for the treatment of Recurrent Respiratory Papillomatosis (RRP) at this year's American Broncho-Esophagological Association (ABEA) program at the Combined Otolaryngology Spring Meetings (COSM) in Boston, Massachusetts.
  • "We are pleased that lead investigator Dr. Ted Mau will have the opportunity to share additional encouraging insights on the safety and immunogenicity of INO-3107 from both cohorts of our recently completed study," said Dr. Mike Sumner, INOVIO's Chief Medical Officer.
  • Details of the ABEA at COSM presentation are as follows:
    Title: Phase 1/2 Open-label, Multicenter Trial Of INO-3107 With Electroporation In Adult Patients With HPV-6 And/or HPV-11-associated Recurrent Respiratory Papillomatosis: Interim Analysis
    The presentation will include new safety, immunological, and demographic data from both cohorts of a Phase 1/2 trial evaluating the safety, tolerability, immunogenicity, and efficacy of INO-3107 in 32 patients with HPV-6 and/or HPV-11-associated RRP.

AGC Biologics Received Bioprocessing Excellence Award in Japan

Retrieved on: 
Wednesday, April 26, 2023
Biotechnology, Pharmaceutical, Genetics, Health, GMP, Hook effect, ABEA, Escherichia coli, AGC, CDMO, Work, Conference, Fine chemical

AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it has received the “Bioprocessing Excellence in Japan” award at the Asia-Pacific Bioprocessing Excellence Awards ceremony for the work and achievements at the AGC Biologics Chiba, Japan site.

Key Points: 
  • AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it has received the “Bioprocessing Excellence in Japan” award at the Asia-Pacific Bioprocessing Excellence Awards ceremony for the work and achievements at the AGC Biologics Chiba, Japan site.
  • AGC Biologics was honored alongside other industry leaders at the 10th Annual Biologics Manufacturing Asia Conference on March 15.
  • AGC Biologics is a CDMO in Japan with microbial and mammalian capabilities backed by a global resource and supply chain network.
  • “AGC Biologics is honored to receive this award showcasing our growing biologics capabilities at our site in Chiba, Japan, and the great work our team members perform every day,” said Jun Takami, General Manager, AGC Biologics Chiba Facility.

Avantor Named Best Bioprocessing Supplier in Cell and Gene Therapy at the Biopharma Excellence Awards India Edition

Retrieved on: 
Monday, April 3, 2023
Gene, Education, Head, ABEA, Best, BEA, Government, Risk, Cell, IMEA, Vaccine, Fine chemical, Chromatography, Avantor

Ganesh Bade - Head of Biopharma India Middle East & Africa (IMEA), Avantor (right) receiving the accolade at the Awards ceremony.

Key Points: 
  • Ganesh Bade - Head of Biopharma India Middle East & Africa (IMEA), Avantor (right) receiving the accolade at the Awards ceremony.
  • Avantor is focused on making valuable contributions to cell and gene therapy production and offers expertise, technology capabilities and commitment to providing solutions.
  • Recently, Avantor was also accorded the Best Bioprocessing Company in Chromatography at the Asia-Pacific Bioprocessing Excellence Awards (ABEA) 2023 (bit.ly/3ZuSbUM) held in Singapore.
  • Ganesh Bade, Head Biopharma India Middle East and Africa (IMEA) at Avantor, said, "Cell and gene therapy is considered a game-changer for the biopharma industry.

Avantor Named Best Bioprocessing Company in Chromatography at the Asia-Pacific Bioprocessing Excellence Awards

Retrieved on: 
Thursday, March 16, 2023
SEAT, Drug development, International Fertilizer Development Center, Education, Chromatography, Government, ABEA, Avantor, Biotechnology, Acceleration, Fine chemical

Industry panel recognizes Avantor's outstanding accomplishments in chromatography instruments, chemicals, and consumables

Key Points: 
  • Industry panel recognizes Avantor's outstanding accomplishments in chromatography instruments, chemicals, and consumables
    Singapore, Mar 16, 2023 - (ACN Newswire) - Avantor, a leading global provider of mission-critical products and services to customers in the life sciences, education, government and advanced technologies & applied materials industries, has been accorded the Best Bioprocessing Company for Chromatography at the Asia-Pacific Bioprocessing Excellence Awards 2023 (ABEA).
  • With over four decades of experience in bioprocessing, Avantor is committed to addressing the complex challenges of downstream chromatography by providing a comprehensive range of equipment, products and services.
  • "Chromatography is one of the most important components in enabling scientific breakthroughs and bringing promising biologics to market effectively.
  • "We are exceptionally proud to have been selected by the panel of industry experts and honored at this year's ceremony as the Best Bioprocessing Company - Chromatography.